HemoShear

OverviewSuggest Edit

HemoShear Therapeutics is a company discovering treatments for rare metabolic disorders in children. Its technology helps to recapitulate diseases using tissue from livers of children born with genetic defects, interrogate the disrupted biochemical processes, explore drug intervention strategies, and select drug candidates with high probabilities of clinical success.

TypePrivate
Founded2008
HQCharlottesville, VA, US
Websitehemoshear.com

Latest Updates

Employees (est.) (Jul 2021)52(+2%)
Cybersecurity ratingBMore

Key People/Management at HemoShear

James Powers

James Powers

Chairman and CEO
Brian Wamhoff

Brian Wamhoff

Chief Operating Officer
Brian A. Johns

Brian A. Johns

Chief Scientific Officer
Gerald F. Cox

Gerald F. Cox

Acting Chief Medical Officer
Aric Holsinger

Aric Holsinger

Chief Financial Officer
Mavis Waller

Mavis Waller

Vice President, Clinical Operations
Show more

HemoShear Office Locations

HemoShear has an office in Charlottesville
Charlottesville, VA, US (HQ)
501 Locust Ave #301
Show all (1)

HemoShear Financials and Metrics

Summary Metrics

Founding Date

2008

HemoShear total Funding

$51.7 m

HemoShear latest funding size

$40 m

Time since last funding

6 months ago

HemoShear investors

HemoShear's latest funding round in February 2021 was reported to be $40 m. In total, HemoShear has raised $51.7 m
Show all financial metrics

HemoShear Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

HemoShear Online and Social Media Presence

Embed Graph

HemoShear News and Updates

HemoShear Therapeutics Announces First Two Patients Dosed in Phase 2 Study of Oral Small Molecule HST5040 for Methylmalonic Acidemia (MMA) and Propionic Acidemia (PA)

CHARLOTTESVILLE, Va., July 22, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, today announced that the first two patients have been dosed in the HERO (HElp Reduce Organic Acids) Phase 2 clinical trial of...

HemoShear Therapeutics Advances Second Novel Drug Target into Horizon Therapeutics plc Early Discovery Pipeline for Gout

CHARLOTTESVILLE, Va., April 21, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP) that was established...

HemoShear Therapeutics Raises $40 Million in Series A Financing to Advance Rare Disease Portfolio

CHARLOTTESVILLE, Va., Feb. 10, 2021 /PRNewswire/ -- HemoShear Therapeutics, Inc., a clinical stage company developing treatments for rare metabolic disorders, has raised $40 million in a Series A financing. Suvretta Capital led the financing along with Janus Henderson Investors, Adage...

HemoShear Therapeutics Identifies Novel Drug Target to Treat NASH in Drug Discovery Partnership with Takeda

CHARLOTTESVILLE, Va., Dec. 10, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical Company Limited ("Takeda") to advance its...

HemoShear Therapeutics Enters into Rare Liver Disease Research Collaboration with Takeda

CHARLOTTESVILLE, Va., Oct. 21, 2020 /PRNewswire/ -- HemoShear Therapeutics, LLC, a privately held clinical stage biotechnology company, has entered into a research collaboration and service agreement with Takeda Pharmaceutical Company Limited ("Takeda"). Under the terms of the agreement,...

HemoShear Therapeutics Receives FDA Fast Track and Rare Pediatric Disease Designations for HST5040 to Treat Methylmalonic Acidemia and Propionic Acidemia

CHARLOTTESVILLE, Va., July 28, 2020 /PRNewswire/ -- HemoShear Therapeutics, a clinical stage company developing treatments for rare metabolic disorders, has received Fast Track and Rare Pediatric Disease designations from the U.S. Food and Drug Administration (FDA) for HST5040, a...
Show more

HemoShear Frequently Asked Questions

  • When was HemoShear founded?

    HemoShear was founded in 2008.

  • Who are HemoShear key executives?

    HemoShear's key executives are James Powers, Brian Wamhoff and Brian A. Johns.

  • How many employees does HemoShear have?

    HemoShear has 52 employees.

  • Who are HemoShear competitors?

    Competitors of HemoShear include Beacon Discovery, Circle Pharma and Scioto Biosciences.

  • Where is HemoShear headquarters?

    HemoShear headquarters is located at 501 Locust Ave #301, Charlottesville.

  • Where are HemoShear offices?

    HemoShear has an office in Charlottesville.

  • How many offices does HemoShear have?

    HemoShear has 1 office.